Optimizing Lead Therapeutic Compounds Against Infectious Diseases

Information

• Research Project
• 9334667

• ApplicationId

  9334667

• Core Project Number

  N01AI000000

• Full Project Number

  272201500015C-3-0-1

• Serial Number

• FOA Number

• Sub Project Id

• Project Start Date

  7/1/2015 - 8 years ago

• Project End Date

  10/15/2017 - 6 years ago

• Program Officer Name

• Budget Start Date

  -

• Budget End Date

  -

• Fiscal Year

  2016

• Support Year

• Suffix

• Award Notice Date

  -

Organizations

• Southwest Research Institute

To support the advancement of promising lead therapeutics to the clinical drug candidate stage for the treatment of infectious diseases. Activities that may be supported include medicinal chemistry and preclinical in vitro and in vivo testing of a lead compound series in order to produce profiles of their efficacy, synthetic feasibility, stability, and toxicity, which will be used to identify a novel small molecule drug candidate for future clinical development.

IC Name

• Activity

  N01

• Administering IC

  AI

• Application Type

• Direct Cost Amount

• Indirect Cost Amount

• Total Cost

  1118039

• Sub Project Total Cost

• ARRA Funded

  False

• CFDA Code

  855

• Ed Inst. Type

• Funding ICs

  NIAID:1118039\

• Funding Mechanism

  Non SBIR/STTR Contracts

• Study Section

• Study Section Name

• Organization Name

  SOUTHWEST RESEARCH INSTITUTE

• Organization Department

• Organization DUNS

  007936842

• Organization City

  SAN ANTONIO

• Organization State

  TX

• Organization Country

  UNITED STATES

• Organization Zip Code

  782385166

• Organization District

  UNITED STATES